Having trouble accessing articles? Reset your cache.

With GeneSight health economics data in hand, Myriad wins UnitedHealth coverage

Myriad Genetics jumped $15.87 (55%) to $45.01 Thursday, lifting its market cap by $1.2 billion to $3.3 billion, after UnitedHealth said it will begin covering its genetic depression test. The decision, which goes into effect Oct. 1,

Read the full 375 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers